公开(公告)号：KR1020140058480A

公开(公告)日：2014-05-14

申请号：KR1020140047606

申请日：2014-04-21

Applicant: 한국과학기술연구원

Inventor： 이창준 ,  조선미 ,  윤보은 ,  추현아 ,  김지윤 ,  김대수

IPC: A61K31/4741 ,  A61K31/4743 ,  A61K31/4745 ,  A61K31/4738 ,  G01N33/53 ,  G01N33/15 ,  G01N33/68 ,  A61P25/28 ,  A61P25/00

CPC classification number: A61K31/44 ,  A61K31/437 ,  A61K31/55

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating neurodegenerative diseases, and a screening method thereof. According to an embodiment of the present invention, by applying the screening method which screens candidate substances for preventing or treating neurodegenerative diseases, a substance for preventing or treating neurodegenerative diseases can be effectively screened. The pharmaceutical composition for preventing or treating neurodegenerative diseases obtained by the screening method can effectively prevents or treats various neurodegenerative diseases.

Abstract translation: 本发明涉及用于预防或治疗神经变性疾病的药物组合物及其筛选方法。 根据本发明的一个实施方案，通过应用筛选候选物质的预防或治疗神经变性疾病的筛选方法，可以有效地筛选用于预防或治疗神经变性疾病的物质。 用于预防或治疗通过筛选方法获得的神经变性疾病的药物组合物可以有效地预防或治疗各种神经变性疾病。

公开(公告)号：KR1020110020387A

公开(公告)日：2011-03-03

申请号：KR1020090077979

申请日：2009-08-24

Applicant: 한국과학기술연구원

Inventor： 이창준 ,  이수정 ,  윤보은

IPC: A61K31/465 ,  A61K31/7105 ,  A61P25/08 ,  A61P25/28

CPC classification number: A61K31/00 ,  A61K31/185 ,  A61K31/196 ,  A61K31/455 ,  A61K31/7105 ,  A61K31/713 ,  A61K38/043 ,  A61K38/08 ,  G01N33/9426 ,  G01N2500/10

Abstract: PURPOSE: A GABA(gamma-aminobutyric acid) release inhibitor containing bestrophin 1 channel inhibitor is provided to enable effective and various treatment for GABA-associated disease symptom. CONSTITUTION: A composition for preventing or treating diseases or symptom due to GABA excessive release contains bestrophin 1 channel inhibitor as an active ingredient. The composition suppresses GABA release in the bovine cerebellum. The bestrophin 1 channel inhibitor is an antisense RNA or shRNA of a nucleotide sequence encoding an anion channel blocker and bestrophin 1 channel. The anion channel blocker is niflumic acid, 5-nitro-2(3-phenylpropylamino)-bazoic acid(NPPB) or 4,4'-diisothiocyanatostylbene-2,2'-disulfonic acid(DIDS). The nucleotide sequence encoding the bestrophin 1 channel is a sequence of sequence number 1 or 2. A composition for preventing or treating diseases due to GABA deficiency contains a bestrophin 1 channel activator as an active ingredient. The activator is a peptide TFLLR and Bradykinin.

Abstract translation: 目的：提供含有bestrophin 1通道抑制剂的GABA（γ-氨基丁酸）释放抑制剂，以有效和各种治疗GABA相关疾病症状。 构成：用于预防或治疗由于GABA过度释放引起的疾病或症状的组合物，含有bestrophin 1通道抑制剂作为活性成分。 该组合物抑制牛小脑中的GABA释放。 bestrophin 1通道抑制剂是编码阴离子通道阻断剂和bestrophin 1通道的核苷酸序列的反义RNA或shRNA。 阴离子通道阻断剂是尼氟酸，5-硝基-2（3-苯基丙基氨基） - 二羧酸（NPPB）或4,4'-二异硫氰基脂肪基-22'-二磺酸（DIDS）。 编码bestrophin 1通道的核苷酸序列是序列号1或2的序列。用于预防或治疗由于GABA缺陷引起的疾病的组合物含有作为活性成分的bestrophin 1通道激活剂。 活化剂是肽TFLLR和缓激肽。

公开(公告)号：KR101438532B1

公开(公告)日：2014-09-12

申请号：KR1020120089402

申请日：2012-08-16

Applicant: 한국과학기술연구원

Inventor： 이창준 ,  조선미 ,  윤보은 ,  추현아 ,  김지윤 ,  김대수

IPC: G01N33/53 ,  G01N33/15 ,  G01N33/68

Abstract: 본 발명은 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물 및 이를 스크리닝하는 방법에 관한 것이다. 일 구체예에 따른 퇴행성 뇌질환의 예방 또는 치료용 후보 물질의 스크리닝 방법에 의하면, 퇴행성 뇌질환의 예방 또는 치료 물질을 효과적으로 스크리닝할 수 있으며, 이에 따른 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물은 여러 퇴행성 뇌질환을 효과적으로 예방 또는 치료할 수 있다.

公开(公告)号：KR1020130020949A

公开(公告)日：2013-03-04

申请号：KR1020120089402

申请日：2012-08-16

Applicant: 한국과학기술연구원

Inventor： 이창준 ,  조선미 ,  윤보은 ,  추현아 ,  김지윤 ,  김대수

IPC: G01N33/53 ,  G01N33/15 ,  G01N33/68

Abstract: PURPOSE: A pharmaceutical composition for preventing or treating neurodegenerative diseases, and a method for screening the same are provided to effectively screen a material which prevents or treats neurodegenerative diseases. CONSTITUTION: A method for screening a pharmaceutical composition for preventing or treating neurodegenerative diseases comprises: a step of contacting a sample to be analyzed with a reactive astrocyte; a step of measuring the reduction of GABA concentration in the reactive astrocyte or GABA release from the reactive astrocyte; and a step of determining a material which prevents or treats neurodegenerative diseases when the sample reduces the GABA concentration or GABA release.

Abstract translation: 目的：提供用于预防或治疗神经变性疾病的药物组合物及其筛选方法，以有效筛选预防或治疗神经变性疾病的材料。 构成：用于筛选用于预防或治疗神经变性疾病的药物组合物的方法包括：将待分析样品与活性星形胶质细胞接触的步骤; 测量来自反应性星形胶质细胞的反应性星形胶质细胞或GABA释放中GABA浓度降低的步骤; 以及当样品降低GABA浓度或GABA释放时，确定预防或治疗神经变性疾病的材料的步骤。

公开(公告)号：KR101154538B1

公开(公告)日：2012-06-13

申请号：KR1020090077979

申请日：2009-08-24

Applicant: 한국과학기술연구원

Inventor： 이창준 ,  이수정 ,  윤보은

IPC: A61K31/465 ,  A61K31/7105 ,  A61P25/08 ,  A61P25/28

CPC classification number: A61K31/00 ,  A61K31/185 ,  A61K31/196 ,  A61K31/455 ,  A61K31/7105 ,  A61K31/713 ,  A61K38/043 ,  A61K38/08 ,  G01N33/9426 ,  G01N2500/10

Abstract: A GABA (gamma-aminobutyric acid) release-inhibiting agent in the cerebellum and a composition for treating pathological symptoms caused by over-release of GABA in the cerebellum, each comprising a Bestrophin 1(Best1) channel inhibitor as an active ingredient; a GABA release-promoting agent in the cerebellum and a composition for treating pathological symptoms caused by the deficit of GABA in the cerebellum, each comprising a Best1 channel activator as an active ingredient; and a method for screening a GABA release-regulating agent in the cerebellum, which uses Best1 channel as target, are provided.